ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.

ClinicalTrials.gov ID: NCT02437318

Public ClinicalTrials.gov record NCT02437318. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 7, 2026, 2:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment

Study identification

NCT ID
NCT02437318
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
572 participants

Conditions and interventions

Conditions

Interventions

  • Alpelisib Drug
  • Fulvestrant Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 100 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 22, 2015
Primary completion
Jun 11, 2018
Completion
Jun 8, 2023
Last update posted
Feb 12, 2025

2015 – 2023

United States locations

U.S. sites
34
U.S. states
22
U.S. cities
34
Facility City State ZIP Site status
Ironwood Cancer and Research Centers Chandler Arizona 85224
Mayo Clinic Arizona Scottsdale Arizona 85259
Highlands Oncology Group Fayetteville Arkansas 72703
Beverly Hills Cancer Center Beverly Hills California 90211
City of Hope National Medical Center Duarte California 91010 3000
Scripps Green Hospital La Jolla California 92037
Kaiser Permanent Southern Californi San Diego California 92120
UCSF San Francisco California 94115
Florida Cancer Specialists Fort Myers Florida 33901
Florida Cancer Specialists-North St. Petersburg Florida 33705
Rush University Medical Center Chicago Illinois 60612
NorthShore University Health System Evanston Illinois 60201
Edward Cancer Center Naperville Illinois 60540
Fort Wayne Medical Oncology Hematology Inc Fort Wayne Indiana 46815
St Francis Health Comprehensive Cancer Center Topeka Kansas 66606-169
Mercy Medical Center Baltimore Maryland 21202
Massachusetts General Hospital Boston Massachusetts 02114
Lahey Clinic Burlington Massachusetts 01805
Detroit Clinical Research Center Owosso Michigan 48867
St Lukes Cancer Institute Kansas City Missouri 64111
St Vincent Frontier Cancer Center Billings Montana 59102
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey 08903
University Hospitals of Cleveland Seidman Cancer Center Cleveland Ohio 44106
Good Samaritan Regional Medical Center Corvallis Oregon 97330
Lancaster General Hospital Lancaster Pennsylvania 17604
Prisma Health Upstate Greenville South Carolina 29615
Avera Cancer Sioux Falls South Dakota 57105
SCRI Oncology Partners Nashville Tennessee 37203
Texas Oncology PA Dallas Presbyterian Hospital Dallas Texas 75231
El Paso Texas Oncology El Paso Texas 79902
Mays Cancer Ctr Uthsa Mdacc San Antonio Texas 78229
Texas Oncology Northeast Texas Tyler Texas 75702
Virginia Cancer Specialists Fairfax Virginia 22031
Wenatchee Valley Medical Center Wenatchee Washington 98801

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 163 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02437318, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 12, 2025 · Synced May 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02437318 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →